Rhumbline Advisers lifted its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 16.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,673 shares of the biopharmaceutical company’s stock after purchasing an additional 10,170 shares during the quarter. Rhumbline Advisers owned 0.12% of Dynavax Technologies worth $1,519,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of DVAX. Cubist Systematic Strategies LLC boosted its stake in Dynavax Technologies by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 3,700 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in Dynavax Technologies by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares in the last quarter. Bank of America Corp DE boosted its stake in Dynavax Technologies by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares in the last quarter. Legal & General Group Plc boosted its stake in Dynavax Technologies by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares in the last quarter. Finally, Wall Street Access Asset Management LLC purchased a new stake in Dynavax Technologies in the second quarter worth approximately $124,000. 70.61% of the stock is owned by institutional investors.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) opened at $19.00 on Thursday. Dynavax Technologies Corporation has a 52 week low of $3.70 and a 52 week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the previous year, the company posted ($0.90) earnings per share. The business’s revenue was down 68.8% on a year-over-year basis. equities analysts predict that Dynavax Technologies Corporation will post -1.72 EPS for the current fiscal year.

Several analysts have issued reports on DVAX shares. Cowen reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. Cantor Fitzgerald upped their target price on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 9th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $26.00 target price on shares of Dynavax Technologies in a research note on Friday, September 1st. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Finally, BidaskClub lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Dynavax Technologies presently has a consensus rating of “Buy” and a consensus price target of $25.17.

ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/14/dynavax-technologies-corporation-dvax-stake-lifted-by-rhumbline-advisers.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related stocks with our FREE daily email newsletter.